14.03
price up icon1.00%   0.09
 
loading
Schlusskurs vom Vortag:
$13.94
Offen:
$14
24-Stunden-Volumen:
260.15K
Relative Volume:
0.15
Marktkapitalisierung:
$888.02M
Einnahmen:
$15.84M
Nettoeinkommen (Verlust:
$-308.48M
KGV:
-2.1651
EPS:
-6.48
Netto-Cashflow:
$-153.08M
1W Leistung:
-0.98%
1M Leistung:
-2.70%
6M Leistung:
-20.27%
1J Leistung:
+216.76%
1-Tages-Spanne:
Value
$13.64
$14.23
1-Wochen-Bereich:
Value
$13.51
$14.71
52-Wochen-Spanne:
Value
$3.73
$19.18

Uniqure N V Stock (QURE) Company Profile

Name
Firmenname
Uniqure N V
Name
Telefon
1-339-970-7000
Name
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Name
Mitarbeiter
209
Name
Twitter
@uniQure_NV
Name
Nächster Verdiensttermin
2024-07-30
Name
Neueste SEC-Einreichungen
Name
QURE's Discussions on Twitter

Vergleichen Sie QURE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
QURE
Uniqure N V
14.04 888.02M 15.84M -308.48M -153.08M -6.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
451.60 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
536.80 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
323.48 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
554.00 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.50 28.51B 3.81B -644.79M -669.77M -6.24

Uniqure N V Stock (QURE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-01 Fortgesetzt Chardan Capital Markets Buy
2024-12-10 Hochstufung Raymond James Outperform → Strong Buy
2024-10-10 Fortgesetzt Raymond James Outperform
2024-02-29 Herabstufung Goldman Buy → Neutral
2023-12-19 Herabstufung Mizuho Buy → Neutral
2022-03-17 Hochstufung UBS Neutral → Buy
2021-06-15 Eingeleitet BTIG Research Buy
2021-05-21 Eingeleitet UBS Neutral
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-04-01 Hochstufung Mizuho Neutral → Buy
2021-01-07 Hochstufung Guggenheim Neutral → Buy
2020-11-24 Eingeleitet H.C. Wainwright Buy
2020-11-11 Eingeleitet Berenberg Buy
2020-11-09 Eingeleitet Jefferies Buy
2020-11-04 Eingeleitet Cantor Fitzgerald Overweight
2020-10-23 Eingeleitet RBC Capital Mkts Outperform
2020-08-25 Eingeleitet Raymond James Strong Buy
2020-07-31 Hochstufung Robert W. Baird Neutral → Outperform
2020-06-25 Herabstufung Mizuho Buy → Neutral
2020-06-25 Herabstufung Robert W. Baird Outperform → Neutral
2020-06-25 Herabstufung Wells Fargo Overweight → Equal Weight
2019-12-03 Eingeleitet Cowen Outperform
2019-12-03 Eingeleitet Goldman Buy
2019-11-05 Eingeleitet Credit Suisse Outperform
2019-10-11 Eingeleitet Stifel Buy
2019-09-25 Eingeleitet Bernstein Outperform
2019-09-12 Eingeleitet Mizuho Buy
2019-07-30 Herabstufung Guggenheim Buy → Neutral
2019-07-08 Bestätigt Cantor Fitzgerald Overweight
2019-04-12 Eingeleitet Piper Jaffray Overweight
2019-03-29 Eingeleitet Robert W. Baird Outperform
Alle ansehen

Uniqure N V Aktie (QURE) Neueste Nachrichten

pulisher
Jun 17, 2025

uniQure: Price And Value Have Caught Up (NASDAQ:QURE) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 13, 2025

uniQure shareholders approve executive compensation, board reappointments By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

uniQure shareholders approve executive compensation, board reappointments - Investing.com

Jun 13, 2025
pulisher
Jun 11, 2025

uniQure (QURE) Appoints Kylie O'Keefe to Advance Global Strategy - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer - Investing.com India

Jun 11, 2025
pulisher
Jun 11, 2025

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer - GlobeNewswire

Jun 11, 2025
pulisher
Jun 11, 2025

uniQure Prepares for Historic Huntington's Disease Treatment Launch with Key Executive Hire - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

uniQure (NASDAQ:QURE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Jun 11, 2025
pulisher
Jun 09, 2025

Learn to Evaluate (QURE) using the Charts - news.stocktradersdaily.com

Jun 09, 2025
pulisher
Jun 06, 2025

uniQure (QURE) Positioned for Growth Amid Regulatory Changes - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

RFK Jr. looks to fast track rare disease drug approvals (updated) - Seeking Alpha

Jun 06, 2025
pulisher
Jun 06, 2025

Bank of America Corp DE Has $1.22 Million Stock Holdings in uniQure (NASDAQ:QURE) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Stock Traders Buy Large Volume of uniQure Call Options (NASDAQ:QURE) - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

stifel reiterates buy rating on uniQure stock after CEO meeting By Investing.com - Investing.com UK

Jun 05, 2025
pulisher
Jun 05, 2025

uniQure (NASDAQ:QURE) Short Interest Update - Defense World

Jun 05, 2025
pulisher
Jun 03, 2025

H.C. Wainwright reaffirms Buy rating on uniQure stock after FDA meeting By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

H.C. Wainwright reaffirms Buy rating on uniQure stock after FDA meeting - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

Chardan Capital Reaffirms Buy Rating for uniQure (NASDAQ:QURE) - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

uniQure aligns with FDA on Huntington’s therapy path By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

uniQure provides regulatory update on AMT-130 for Huntington’s Disease - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

UniQure Reaches Alignment With FDA on Potential Huntington's Disease Gene Therapy - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Transcript : UniQure N.V.Special Call - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

UniQure Provides Regulatory Update On Amt-130 For Huntington'S Disease - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

uniQure (QURE) Advances Gene Therapy for Huntington's Disease wi - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

uniQure aligns with FDA on Huntington’s therapy path - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

uniQure (QURE) Advances Gene Therapy for Huntington's Disease with FDA Alignment | QURE Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

uniQure Advances AMT-130 for Huntington's Disease with FDA Alignment, BLA Submission Planned for Q1 2026 - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

FDA Green Lights Accelerated Approval Plan for First-Ever Huntington's Disease Gene Therapy Treatment - Stock Titan

Jun 02, 2025
pulisher
May 31, 2025

uniQure (NASDAQ:QURE) Given “Buy” Rating at Chardan Capital - Defense World

May 31, 2025
pulisher
May 30, 2025

HC Wainwright maintains Buy rating on uniQure stock, $70 target By Investing.com - Investing.com UK

May 30, 2025
pulisher
May 30, 2025

uniQure (NASDAQ:QURE) Receives Buy Rating from HC Wainwright - Defense World

May 30, 2025
pulisher
May 29, 2025

QURE: HC Wainwright & Co. Reiterates Buy Rating for uniQure | QU - GuruFocus

May 29, 2025
pulisher
May 29, 2025

uniQure presents case study of first patient dosed with AMT-260 - TipRanks

May 29, 2025
pulisher
May 29, 2025

uniQure (QURE) Gains Support Following Positive Data from Epilep - GuruFocus

May 29, 2025
pulisher
May 29, 2025

uniQure (QURE) Unveils Key Data from Gene Therapy Trial | QURE S - GuruFocus

May 29, 2025
pulisher
May 29, 2025

uniQure early AMT-260 data encouraging, says H.C. Wainwright - TipRanks

May 29, 2025
pulisher
May 29, 2025

uniQure (QURE) Unveils Key Data from Gene Therapy Trial | QURE Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

uniQure Presents Clinical Case Study of First Patient Dosed - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) | QURE Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Revolutionary Gene Therapy Cuts Epilepsy Seizures by 92% in First Patient DataUniQure's Breakthrough - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Down 40% in 2025, Should You Buy the Dip in Marvell Stock? - The Globe and Mail

May 29, 2025
pulisher
May 28, 2025

Long Term Trading Analysis for (QURE) - news.stocktradersdaily.com

May 28, 2025
pulisher
May 28, 2025

uniQure's AMT-130 Gene Therapy Warrants An Upgrade (NASDAQ:QURE) - Seeking Alpha

May 28, 2025
pulisher
May 27, 2025

Northern Trust Corp Buys 1,923 Shares of uniQure (NASDAQ:QURE) - Defense World

May 27, 2025
pulisher
May 26, 2025

Millennium Management LLC Cuts Position in uniQure (NASDAQ:QURE) - Defense World

May 26, 2025
pulisher
May 24, 2025

uniQure (NASDAQ:QURE) Upgraded at Wall Street Zen - Defense World

May 24, 2025
pulisher
May 23, 2025

uniQure N.V. (QURE) Stock Analysis: Exploring a 133.81% Potential Upside in Biotechnology - DirectorsTalk Interviews

May 23, 2025
pulisher
May 22, 2025

Fed. Circ. Backs Pfizer Win Against Gene Therapy Patents - Law360

May 22, 2025
pulisher
May 22, 2025

Stock Traders Purchase High Volume of Put Options on uniQure (NASDAQ:QURE) - Defense World

May 22, 2025

Finanzdaten der Uniqure N V-Aktie (QURE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Uniqure N V-Aktie (QURE) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
POST LEONARD E
Director
Jun 20 '25
Sale
14.45
2,112
30,518
29,937
Kaye Jack
Director
Jun 20 '25
Sale
14.45
2,112
30,518
20,439
Jacques Rachelle Suzanne
Director
Jun 20 '25
Sale
14.45
2,112
30,518
28,346
Gut Robert
Director
Jun 20 '25
Sale
14.45
3,336
48,205
56,879
Balachandran Madhavan
Director
Jun 20 '25
Sale
14.45
2,112
30,518
37,697
Meek David D.
Director
Jun 20 '25
Sale
14.45
2,112
30,518
34,190
Potts Jeannette
Chief Legal Officer
Jun 16 '25
Sale
15.14
4,670
70,704
115,073
Kapusta Matthew C
CEO, Managing Director
Mar 04 '25
Sale
10.29
28,341
291,629
651,454
Abi-Saab Walid
Chief Medical Officer
Mar 04 '25
Sale
10.29
1,350
13,891
151,903
KLEMT CHRISTIAN
Chief Financial Officer
Mar 04 '25
Sale
10.29
10,438
107,407
217,730
$20.87
price up icon 0.99%
$35.78
price down icon 0.78%
$21.44
price up icon 0.99%
$98.77
price down icon 2.03%
$108.80
price up icon 2.21%
biotechnology ONC
$245.50
price up icon 1.42%
Kapitalisierung:     |  Volumen (24h):